Fresenius Kabi Oncology Key Ratios
NSE: FKONCO | BSE: 532545
₹132.50
₹0.45
(0.34%)
As on 02-Jan-2014IST
Market cap
₹2,255 Cr
Revenue (TTM)
₹813 Cr
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -11.95 | -58.71 | -36.09 | 6.81 | 5.24 |
| EBIT | -26.43 | -197.23 | -178.40 | 43.29 | 23.70 |
| Net Profit | -14.26 | -205.85 | -213.45 | 28.31 | 31.45 |
| EPS | -14.26 | -205.84 | -213.45 | 28.31 | 6.18 |
| Book Value | -- | -- | 5.70 | 4.67 | 4.17 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 6.41 | 5.43 | 9.29 | 6.44 | 3.51 |
| Net Margin
| 7.17 | -5.22 | 8.86 | 6.65 | 5.99 |
| Return on equity
| 4.41 | -25.86 | 5.47 | 4.15 | 3.61 |
| Return on Capital
| 5.84 | -3.26 | 7.33 | 5.42 | 4.77 |
| Return on Assets
| 3.05 | -2.56 | 3.88 | 2.76 | 2.51 |
| Debt to Equity (x)
| -- | -- | 0.08 | 0.12 | 0.12 |
Profitability
ROCE
7.33
Lower than Peers by 7.39
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
7.33
|
5.42
|
4.77
|
6.67
|
-40.47
|
|
Peer Median
|
14.72
|
18.85
|
11.60
|
11.89
|
--
|
ROE
5.47
Lower than Peers by 6.20
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
5.47
|
4.15
|
3.61
|
5.52
|
-148.03
|
|
Peer Median
|
11.67
|
14.92
|
11.46
|
13.43
|
--
|
ROA
3.88
Lower than Peers by 3.97
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
3.88
|
2.76
|
2.51
|
2.29
|
-24.27
|
|
Peer Median
|
7.86
|
9.06
|
6.44
|
7.03
|
--
|
EBIT Margin
9.29
Lower than Peers by 5.75
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
9.29
|
6.44
|
3.51
|
3.85
|
4.10
|
|
Peer Median
|
15.03
|
14.71
|
12.37
|
16.50
|
--
|
Net Margin
8.86
Lower than Peers by 0.47
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
8.86
|
6.65
|
5.99
|
5.04
|
-52.62
|
|
Peer Median
|
9.33
|
8.49
|
10.02
|
10.49
|
--
|
Cash Profit Margin
15.64
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
15.64
|
14.38
|
13.85
|
13.27
|
-46.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
3.39
Lower than Peers by 6.88
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
3.39
|
9.66
|
7.47
|
10.73
|
-4.33
|
|
Peer Median
|
10.27
|
11.85
|
9.08
|
13.45
|
--
|
EBIT Growth
49.07
Higher than Peers by 24.93
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
49.07
|
101.46
|
-2.03
|
3.93
|
-5.28
|
|
Peer Median
|
24.15
|
28.00
|
-3.12
|
18.27
|
--
|
Net Profit Growth
38.61
Higher than Peers by 8.32
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
38.61
|
19.67
|
27.35
|
110.58
|
-1,856.14
|
|
Peer Median
|
30.29
|
36.51
|
-0.85
|
27.20
|
--
|
EPS Growth
38.61
Higher than Peers by 14.11
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
38.61
|
19.68
|
27.34
|
103.64
|
-1,856.11
|
|
Peer Median
|
24.50
|
--
|
-6.82
|
16.28
|
--
|
Book Value Growth
5.70
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
5.70
|
4.34
|
3.98
|
2,002.64
|
-85.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.08
Lower than Peers by 0.14
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
0.08
|
0.12
|
0.12
|
0.02
|
10.15
|
|
Peer Median
|
0.23
|
0.20
|
0.15
|
0.15
|
--
|
Short term debt to equity ratio
0.06
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
0.06
|
--
|
--
|
--
|
4.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.84
Higher than Peers by 2.05
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
3.84
|
2.64
|
3.11
|
3.38
|
0.73
|
|
Peer Median
|
1.79
|
1.96
|
2.08
|
1.89
|
--
|
Quick Ratio
1.98
Higher than Peers by 0.51
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
1.98
|
1.46
|
1.65
|
1.75
|
0.32
|
|
Peer Median
|
1.47
|
1.44
|
1.58
|
1.64
|
--
|
Interest Coverage
11.64
Higher than Peers by 2.21
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
11.64
|
11.77
|
6.43
|
3.88
|
-8.27
|
|
Peer Median
|
9.42
|
8.58
|
15.41
|
15.38
|
--
|
Operating Efficiency
Debtors to sales
46.76
Higher than Peers by 20.94
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
46.76
|
44.53
|
53.20
|
53.28
|
37.10
|
|
Peer Median
|
25.82
|
26.12
|
22.96
|
20.72
|
--
|
Asset Turnover
0.42
Lower than Peers by 0.33
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
0.42
|
0.40
|
0.40
|
0.43
|
0.44
|
|
Peer Median
|
0.75
|
0.77
|
0.65
|
0.61
|
--
|
Receivable days
163.95
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
163.95
|
169.80
|
187.55
|
158.38
|
114.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
262.96
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
262.96
|
274.03
|
278.04
|
268.55
|
275.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
179.42
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
179.42
|
286.30
|
301.74
|
330.13
|
398.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
247.48
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
247.48
|
157.53
|
163.86
|
96.80
|
-8.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.70
|
33.48
|
37.74
|
60.11
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.72
|
4.21
|
3.22
|
3.92
|
--
|
EV/EBITDA
0.99
Lower than Peers by 29.24
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
0.99
|
0.25
|
1.18
|
0.40
|
5.28
|
|
Peer Median
|
30.23
|
29.90
|
28.81
|
25.94
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Fresenius Kabi Oncology
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4,851
|
2,099
|
15,272
|
13,501
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
